Legal & General Group
TRVI icon

Legal & General Group’s Trevi Therapeutics TRVI Stock Holding History

Legal & General Group’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$761K Sell
63,819
-17,854
-22% -$200K ﹤0.01% 2231
2025
Q4 		$1.02M Sell
81,673
-299
-0.4% -$3.46K ﹤0.01% 2209
2025
Q3 		$750K Buy
81,972
+73,526
+871% +$551K ﹤0.01% 2323
2025
Q2 		$46.2K Buy
8,446
+984
+13% +$6.12K ﹤0.01% 2729
2025
Q1 		$46.9K Buy
7,462
+920
+14% +$4.39K ﹤0.01% 2734
2024
Q4 		$27K Hold
6,542
– – ﹤0.01% 2926
2024
Q3 		$21.9K Hold
6,542
– – ﹤0.01% 3016
2024
Q2 		$19.5K Buy
6,542
+2,568
+65% +$7.13K ﹤0.01% 3026
2024
Q1 		$13.7K Hold
3,974
– – ﹤0.01% 3125
2023
Q4 		$5.33K Hold
3,974
– – ﹤0.01% 3318
2023
Q3 		$8.66K Hold
3,974
– – ﹤0.01% 3295
2023
Q2 		$9.5K Buy
+3,974
New +$10K ﹤0.01% 3325

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return